Skip to main content

Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis

BioDrugs volume 30, pages 207–217 (2016)Cite this article

Abstract

Background

Evidence-based studies are increasingly being focused on evaluating the efficacy and safety of adalimumab (ADA) for moderately to severely active ulcerative colitis (UC). However, the dosage pattern of ADA for UC management is still not clear.

Objective

A meta-analysis was conducted to evaluate the efficacy and safety of different ADA dosage regimens for moderately to severely active UC.

Methods

The Medline, EMBASE, ISI Web of Knowledge, and Cochrane databases were searched from their inception to January 2015. Randomized controlled trials (RCTs) comparing ADA with placebo were eligible for initial inclusion. The efficacy and side effects were evaluated for ADA 160/80 (ADA 160/80 mg at weeks 0/2 and then 40 mg at weeks 4 and 6), and ADA 80/40 (ADA 80/40 mg at weeks 0/2 and then 40 mg at weeks 4 and 6) induction therapy, with ADA 40 mg every other week (EOW) for maintenance therapy of 52 weeks. The pooled risk ratio (RR) and its 95 % confidence interval (CI) were calculated.

Results

Three RCTs were included. All of the studies were considered to have a low risk of bias. ADA 160/80 was more effective than placebo for induction of clinical remission (RR 1.62, 95 % CI 1.15–2.29), clinical response (RR 1.37, 95 % CI 1.19–1.59), mucosal healing (RR 1.27, 95 % CI 1.08–1.50), and inflammatory bowel disease questionnaire (IBDQ) response (RR 1.22, 95 % CI 1.05–1.43) and did not increase adverse events (RR 1.10, 95 % CI 0.95–1.27). Compared with placebo, ADA 80/40 did not show significant differences for induction of clinical remission and clinical response and did not increase adverse events. ADA 40 mg EOW was superior to placebo in maintaining clinical remission (RR 2.38, 95 % CI 1.57–3.59), clinical response (RR 1.69, 95 % CI 1.29–2.21), mucosal healing (RR 1.69, 95 % CI 1.26–2.28), and IBDQ response (RR 1.73, 95 % CI 1.28–2.34). Compared with placebo, ADA 40 mg EOW increased adverse events (RR 1.28, 95 % CI 1.06–1.54).

Conclusion

ADA 160/80 was a safe and effective treatment for induction management of moderately to severely active UC, but the benefits of ADA 80/40 application were limited. ADA 40 mg EOW was effective for maintenance management of UC. Additional well designed RCTs are needed to confirm these results.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–90.

    Article  PubMed  Google Scholar 

  2. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.

    Article  PubMed  Google Scholar 

  3. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–9.

    Article  PubMed  Google Scholar 

  4. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.

    Article  PubMed  Google Scholar 

  5. Ouyang Q, Xue LY. Inflammatory bowel disease in the 21st century in China: turning challenges into opportunities. J Dig Dis. 2012;13:195–9.

    Article  PubMed  Google Scholar 

  6. Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Dig Dis. 2010;11:76–82.

    Article  PubMed  Google Scholar 

  7. Sands BE, Kaplan GG. The role of TNF alpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930–41.

    CAS  Article  PubMed  Google Scholar 

  8. Kemp R, Dunn E, Schultz M. Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs. 2013;27:585–90.

    CAS  Article  PubMed  Google Scholar 

  9. Song YN, Zheng P, Xiao JH, Lu ZJ. Efficacy and safety of adalimumab for the Crohn’s disease: a systematic review and meta-analysis of published randomized placebo-controlled trials. Eur J Clin Pharmacol. 2014;70:907–14.

    CAS  Article  PubMed  Google Scholar 

  10. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol. 1999;34:66–74.

    CAS  Article  PubMed  Google Scholar 

  11. Nielsen OH, Gionchetti P, Ainsworth M, Vainer B, Campieri M, Borregaard N, Kjeldsen L. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-α in ulcerative colitis. Am J Gastroenterol. 1999;94:2923–8.

    CAS  PubMed  Google Scholar 

  12. Burness CB, Keating GM. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis. BioDrugs. 2013;27:247–62.

    CAS  Article  PubMed  Google Scholar 

  13. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–7.

    CAS  Article  PubMed  Google Scholar 

  14. Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660–71.

    CAS  Article  PubMed  Google Scholar 

  15. Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, Bonovas S. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704–11.

    Article  PubMed  Google Scholar 

  16. Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8:571–81.

    Article  PubMed  Google Scholar 

  17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.

    Article  PubMed  Google Scholar 

  18. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287–96.

    CAS  PubMed  Google Scholar 

  19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.

    CAS  Article  PubMed  Google Scholar 

  20. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lemann M, Marteau P, Rutgeerts P, Scholmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.

    Article  PubMed  Google Scholar 

  21. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011): the Cochrane Collaboration. 2011. Available from http://www.cochrane-handbook.org.

  22. Sandborn WJ, Colombel JF, D’Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37:204–13.

    CAS  Article  PubMed  Google Scholar 

  23. Reinisch W, Sandborn WJ, Panaccione R, Huang B, Pollack PF, Lazar A, Thakkar RB. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013;19:1700–9.

    Article  PubMed  Google Scholar 

  24. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–65.

    CAS  Article  PubMed  Google Scholar 

  25. Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A, Thakkar RB, Watanabe M. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283–94.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial. Gastroenterology. 2006;130:323–33.

    CAS  Article  PubMed  Google Scholar 

  27. Colombel J, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Author notes

    Affiliations

    1. School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China

      Xinlin Chen, Chuanwei Mo & Qian Xu

    2. The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China

      Jiangtao Hou, Bin Chen, Zhengkun Hou & Fengbin Liu

    3. The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

      Yujie Yuan & Weiling He

    4. The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China

      Chaoyuan Huang & Haiwen Li

    5. Guangdong Province Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China

      Tianwen Liu

    Authors
    1. Xinlin Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jiangtao Hou
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yujie Yuan
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Chaoyuan Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Tianwen Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Chuanwei Mo
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Haiwen Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Bin Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Qian Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Zhengkun Hou
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Weiling He
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Fengbin Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Weiling He or Fengbin Liu.

    Ethics declarations

    Funding

    This study was funded by the National Natural Science Foundation of China (No: 81403296, 81373786), the Outstanding Youth Foundation of Guangdong Province colleges and universities (YQ2015041), the Young Talents Foundation of Guangzhou University of Chinese Medicine (QNYC20140101), and Science Program for Overseas Scholar of Guangzhou University of Chinese Medicine (Torch Program: XH20140105).

    Author contributions

    XC carried out the design, interpreted the results and wrote the manuscript. JH participated in the study design, extracted the data and wrote the manuscript. YY and TL modified the manuscript. CH contributed to the discussion. CM, HL and QX performed the statistical analyses and interpreted the results. BC and ZH assessed the risk of bias. WH and FL conceived the study and wrote the manuscript. All authors read and approved the final manuscript.

    Conflict of interest

    XC, JH, YY, CH, TL, CM, HL, BC, QX, ZH, WH and FL declare that they have no conflicts of interest.

    Additional information

    X. Chen and J. Hou contributed equally to this article.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (DOC 73 kb)

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Chen, X., Hou, J., Yuan, Y. et al. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. BioDrugs 30, 207–217 (2016). https://doi.org/10.1007/s40259-016-0173-6

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40259-016-0173-6

    Keywords

    • Ulcerative Colitis
    • Risk Ratio
    • Adalimumab
    • Clinical Remission
    • Mucosal Healing